Immunomodulator Forphenicinol

Date:December 22 2020Web Page No:90016

Forphenicinol does not inhibit alkaline phosphatase, binds to cell surface enzymes, and exhibits biological activities such as enhanced delayed hypersensitivity, enhanced macrophage phagocytosis, antitumor effects on transplanted tumors, and enhanced resistance to Pseudomonas aeruginosa infection in mice, while being extremely low toxicity 1, 2).
Forphenicinol was developed from Forphenicine (#09636), an alkaline phosphatase inhibitor isolated from the broth of actinomycetes.

Forphenicinol-Structure

Specification

CAS#71522-58-2
Molecular FormulaC9H11NO4
Molecular Weight197.190
SourceSynthetic derivative of forphenicine
Purity> 90% (HPLC)
SolubilitySoluble in MeOH, H2O
Insoluble in Hexane

Go back to index

Application Note

Forphenicinol is a synthesized derivative of forphenicine, the inhibitor of alkaline phosphatase produced by Streptomyces 3, 4).

  • Forphenicinol augments delayed-type hypersensitivity (DTH) response induced by both sheep red blood cells (SRBC) or oxazolone by oral administration of 1-100 μg/mouse 1).
  • The treatment with forphenicinol restores DTH in mice immuno-suppressed by cyclophosphamide to normal response at 100 μg/mouse 1).
  • Phagocytosis by peritoneal macrophages is enhanced in vivo and in vitro 1).
  • Forphenicinol is effective in increasing the production of the colony-forming unit in culture (CFU-C) in the presence of colony stimulating factor and partially prevents the reduction of leucocyte counts caused by mitomycin C 1).
  • Ehrlich carcinoma is suppressed by treatment with 0.08-0.31 mg/kg/day of forphenicinol given for 5-10 days after tumor inoculation but it does not show antitumor effect in larger doses 2).
  • IMC carcinoma is also suppressed by treatment with 0.5-5 mg/kg/day given for 5-8 days after the inoculation 2).
  • Forphenicinol enhances the antitumor effect of 6-mercaptopurine, aclacinomycin or cyclophosphamide 2).
  • Forphenlcinol shows a protective effect on mouse model of Pseudomonas aeruginosa infection 2).
  • When forphenicinol was orally administered to patients with chronic respiratory tract infections, infectious episodes and suppressor T cells reduced. It suggests that it is useful 5, 6).

Go back to index

Reference

  1. Ishizuka M., et al., J. Antibiot., 35 (8), 1,042~1,048 (1982). [PMID:7142005]
  2. Ishizuka M., et al., J. Antibiot., 35 (8), 1,049~1,054 (1982). [PMID:7142006]
  3. Morishima H., et al., J. Antibiot., 35 (11), 1,500~1,506 (1982). [PMID:7161189]
  4. Aoyagi T., et al., J. Antibiot., 31 (3), 244~246 (1978). [PMID:348665]
  5. Matsumoto K., et al., Kansenshogaku Zasshi., 59 (7), 766~776 (1985). [PMID:3932556]
  6. Yoshimura K., et al., Kansenshogaku Zasshi., 59 (10), 996~1,004 (1985). [PMID:3936891]

IMC banner

[Date : June 25 2024 00:08]

Detail Product Name Product Code Supplier Size Price
Forphenicinol,Immunomodifier
DatasheetThis may not be the latest data sheet.
09637 IMCInstitute of Microbial Chemistry 1 mg $500

Description
Storage 4°C CAS 71522-58-2
Link

Bioactive Compounds

[Date : June 25 2024 00:08]

Forphenicinol,Immunomodifier


  • Product Code: 09637
  • Supplier: IMC
  • Size: 1mg
  • Price: $500

Description
Storage 4°C CAS 71522-58-2
Link

Bioactive Compounds

Go back to index

CONTACT

export@funakoshi.co.jp

  • Prices are for USA / Canada customers. Prices do not include shipping and handling charges, VAT, import tariffs and service charge etc.
  • Please note that Product Information or Price may change without notice.